Breast Cancer Pipeline Therapeutics, Treatment Drugs, Clinical Trials, and Companies 2024

DelveInsight's, "Breast Cancer Pipeline Insight 2024" report provides comprehensive insights about 120+ Breast Cancer companies and 130+ pipeline drugs in the Breast Cancer pipeline landscape. It covers the Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Breast Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Breast Cancer Pipeline. Dive into DelveInsight's comprehensive report today! @ Breast Cancer Pipeline Outlook- https://www.delveinsight.com/sample-request/breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Breast Cancer Pipeline Report
• In December 2024:- UNICANCER- Phase II, Open Label Study of DS-8201a, an Anti-HER2-antibody Drug Conjugate (ADC) for Advanced Breast Cancer Patients, With Biomarkers Analysis to Characterize Response/Resistance to Therapy.
• In December 2024:- Eli Lilly and Company- This study will evaluate the effect of adding abemaciclib to fulvestrant for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that progressed or recurred after previous treatment with a type of drug known as a CDK4/6 inhibitor and endocrine therapy. Participation could last up to 5 years, depending on how you and your tumor respond.
• In December 2024:- US Oncology Research- This is a Phase I/II, open-label dose-escalation study designed to evaluate the maximum tolerated dose (MTD) and dose-limiting side effects of ibrutinib (560 or 840 or 420 mg daily oral dose), given in combination with trastuzumab administered through the vein, in patients with HER2-amplified Metastatic Breast Cancer that has gotten worse after prior therapy with ado-trastuzumab emtansine (T-DM1).
• DelveInsight's Breast Cancer pipeline report depicts a robust space with 120+ Breast Cancer companies working to develop 130+ pipeline therapies for Breast Cancer treatment.
• The leading Breast Cancer Companies working in the market include Byondis, Tanvex Biopharma, Prestige BioPharma, EirGenix, AMbrx, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Roche, Jiangsu Alphamab Oncology Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., RemeGen, Shanghai Henlius Biotech, Merus N.V., Hangzhou DAC Biotech, Lepu Biopharma, Zymeworks, Klus Pharma Inc., Bolt Biotherapeutics, GeneQuantum Healthcare, ALX Oncology, Precirix, BriaCell Therapeutics Corporation, Bliss Biopharmaceutical, BioInvent International, Incyte Corporation, Triumvira Immunologics, Inc., Horizon Therapeutics, and others.
• Promising Breast Cancer Pipeline Therapies in the various stages of development includes Oraxol, ARV-471, Ribociclib, E7389, Trastuzumab, GM-CSF, GM-CSF, Trastuzumab, Paclitaxel, Gemcitabine/Carboplatin, Iniparib, and others.

Stay ahead with the most recent pipeline outlook for Breast Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Breast Cancer Treatment- https://www.delveinsight.com/sample-request/breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Breast Cancer Emerging Drugs Profile
• SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.
SHR-A1811 is an innovative HER2-targeted antibody-drug conjugate with a topoisomerase I payload conjugated to an anti-HER-2 mAb by a cleavable linker. Once bound to HER2 expressing tumor cells, the ADC is internalized and the linker releases the toxin, leading to tumor cell death. It can bind to the cell membrane surface of HER2 expressing cells, and then enter the cells to reach the lysosome to release small Molecular toxins eventually induce tumor cell apoptosis, combining the high targeting of antibodies and the powerful killing power of cytotoxic drugs on target cells. Preclinical research results show that SHR-A1811 has good anti-tumor activity, safety, tolerability and pharmacokinetic characteristics, or can further improve drug resistance, enhance efficacy, meet clinical needs, and provide more cancer patients multiple choice. Currently, the drug is in the Phase III stage of its development for the treatment of Breast Cancer.

• HLX11: Shanghai Henlius Biotech
HLX11 is a pertuzumab biosimilar developed by Henlius independently in line with relevant regulations and guidelines on biosimilars in China and the European Union (EU), which can be potentially used in combination with trastuzumab and chemotherapy as neoadjuvant or adjuvant treatment for HER2-positive early breast cancer and in combination with trastuzumab and docetaxel in patients with HER2-positive metastatic or unresectable locally recurrent breast cancer patients. HLX11 can specifically bind with the subdomain II of HER2 extracellular domain and inhibit the heterodimerisation of HER2 and other HER family receptors, i.e., EGFR, HER3, and HER4. This will inhibit signal transduction of relevant pathways and lead to the stop of growth and apoptosis of tumour cells. In the meantime, HLX11 can also enhance the tumour-killing activity of immune cells via antibody-dependent cell cytotoxicity. Currently, the drug is in the Phase III stage of its development for the treatment of HER2 positive Breast Cancer.

• Praluzatamab ravtansine: CytomX Therapeutics
Praluzatamab ravtansine (CX-2009) is a conditionally activated Probody drug conjugate (PDC) comprising an anti-CD166 mAb conjugated to DM4, with a protease-cleavable linker and a peptide mask that limits target engagement in normal tissue and circulation. The tumor microenvironment is enriched for proteases capable of cleaving the linker, thereby releasing the mask, allowing for localized binding of CX-2009 to CD166. Currently, the drug is in the Phase II stage of its development for the treatment of Breast Cancer.

• MCLA-128: Merus N.V.
MCLA-128 is an antibody-dependent cell-mediated cytotoxicity (ADCC) -enhanced Biclonics® that utilizes Merus Dock & Block® mechanism and inhibits the neuregulin/HER3 tumor-signaling pathway in solid tumors. MCLA-128 is believed to target the HER3 signaling pathway and to overcome the resistance of tumor cells to HER2-targeted therapies using two mechanisms: blocking growth and survival pathways to stop tumor expansion and recruitment and enhancement of immune effector cells to eliminate the tumor. The therapeutic candidate is a full-length IgG bi-specific antibody that acts by targeting HER2 and HER3. It is an antibody-dependent cellular cytotoxicity (ADCC)-enhanced Biclonic, which is developed based on Biclonics ENGAGE platform. Currently the drug is in the Phase II stage of clinical trial evaluation for the treatment of Breast Cancer.

• DX126 262: Hangzhou DAC Biotech
DX-126262 is under development for the treatment of HER2-positive or HER2-mutated unresectable locally advanced or metastatic non-squamous NSCLC, Breast Cancer, breast cancer. The drug candidate is an antibody drug conjugate comprising recombinant humanized anti-Her2 monoclonal antibody conjugated to Tub-114. It is formulated as lyophilized powder and administered via intravenous route of administration. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of HER2-positive Breast Cancer.

Explore groundbreaking therapies and clinical trials in the Breast Cancer Pipeline. Access DelveInsight's detailed report now! @ New Breast Cancer Drugs- https://www.delveinsight.com/sample-request/breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Breast Cancer Companies
Byondis, Tanvex Biopharma, Prestige BioPharma, EirGenix, AMbrx, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Roche, Jiangsu Alphamab Oncology Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., RemeGen, Shanghai Henlius Biotech, Merus N.V., Hangzhou DAC Biotech, Lepu Biopharma, Zymeworks, Klus Pharma Inc., Bolt Biotherapeutics, GeneQuantum Healthcare, ALX Oncology, Precirix, BriaCell Therapeutics Corporation, Bliss Biopharmaceutical, BioInvent International, Incyte Corporation, Triumvira Immunologics, Inc., Horizon Therapeutics, and others

Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Breast Cancer Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Unveil the future of Breast Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Breast Cancer Market Drivers and Barriers- https://www.delveinsight.com/sample-request/breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Breast Cancer Pipeline Report
• Coverage- Global
• Breast Cancer Companies- Byondis, Tanvex Biopharma, Prestige BioPharma, EirGenix, AMbrx, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Roche, Jiangsu Alphamab Oncology Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., RemeGen, Shanghai Henlius Biotech, Merus N.V., Hangzhou DAC Biotech, Lepu Biopharma, Zymeworks, Klus Pharma Inc., Bolt Biotherapeutics, GeneQuantum Healthcare, ALX Oncology, Precirix, BriaCell Therapeutics Corporation, Bliss Biopharmaceutical, BioInvent International, Incyte Corporation, Triumvira Immunologics, Inc., Horizon Therapeutics, and others.
• Breast Cancer Pipeline Therapies- Oraxol, ARV-471, Ribociclib, E7389, Trastuzumab, GM-CSF, GM-CSF, Trastuzumab, Paclitaxel, Gemcitabine/Carboplatin, Iniparib, and others.
• Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Breast Cancer Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Breast Cancer Companies, Key Products and Unmet Needs- https://www.delveinsight.com/sample-request/breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Breast Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Breast Cancer- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. MCLA-128: Merus N.V.
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. DX126 262: Hangzhou DAC Biotech
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. ES2B C001: ExpreS2ion Biotechnologies
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Breast Cancer Companies
21. Breast Cancer Products
22. Breast Cancer Unmet Needs
23. Breast Cancer Market Drivers and Barriers
24. Breast Cancer Future Perspectives and Conclusion
25. Breast Cancer Analyst Views
26. Breast Cancer Companies
27. Appendix

List of the Top Selling Market Research Reports in 2024

Celiac Disease Market: https://www.delveinsight.com/report-store/celiac-disease-cd-market
Coronary Stents Market: https://www.delveinsight.com/report-store/coronary-stents-market-market
CXCR Inhibitors Market: https://www.delveinsight.com/report-store/selective-inhibitor-of-the-cxcr4-chemokine-receptor-market-forecast
Diabetic Gastroparesis Market: https://www.delveinsight.com/report-store/gastroparesis-market
Fertility Monitoring Devices Market: https://www.delveinsight.com/report-store/fertility-monitoring-devices-fertility-testing-devices-market
Phototherapies for Psoriasis Market: https://www.delveinsight.com/report-store/phototherapies-for-psoriasis-market
Pipeline Assessment Services: https://www.delveinsight.com/consulting/pipeline-assessment-services
Ranibizumab Biosimilars Market: https://www.delveinsight.com/report-store/ranibizumab-biosimilars-insight
Rhinitis Market: https://www.delveinsight.com/report-store/rhinitis-market
Skin Grafting Devices Market: https://www.delveinsight.com/report-store/skin-grafting-devices-market
Spinal Implants Market: https://www.delveinsight.com/report-store/spinal-implants-market
Surgical Sealant Market: https://www.delveinsight.com/report-store/surgical-sealant-and-adhesives-market
Thrombectomy Devices Market: https://www.delveinsight.com/report-store/thrombectomy-devices-market
Venous Ulcer Market: https://www.delveinsight.com/report-store/venous-leg-ulcer-market
ADHD Market: https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Bacterial Meningitis Market: https://www.delveinsight.com/report-store/meningococcal-meningitis-market
Heart Pump Devices Market: https://www.delveinsight.com/report-store/heart-pump-device-market
Meningococcal Meningitis Market: https://www.delveinsight.com/report-store/meningococcal-meningitis-market
Percutaneous Arterial Closure Device Market: https://www.delveinsight.com/report-store/vascular-closure-devices-market
Pouchitis Market: https://www.delveinsight.com/report-store/pouchitis-market
Respiratory Syncytial Virus Market: https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-market
Shingles Market: https://www.delveinsight.com/report-store/shingles-market
Artificial Disc Market: https://www.delveinsight.com/report-store/artificial-disc-market
Avascular Necrosis Market: https://www.delveinsight.com/report-store/avascular-necrosis-market
Embolotherapy Market: https://www.delveinsight.com/report-store/embolotherapy-market
Orthopedic Power Devices Market: https://www.delveinsight.com/report-store/orthopedic-power-devices-market
Perennial Allergic Rhinitis Market: https://www.delveinsight.com/report-store/allergic-rhinitis-market
Plaque Psoriasis Market: https://www.delveinsight.com/report-store/plaque-psoriasis-market
Psoriasis Vulgaris Market: https://www.delveinsight.com/report-store/psoriasis-vulgaris-market
Transcatheter Heart Valve Replacement Devices Market: https://www.delveinsight.com/report-store/transcatheter-aortic-valve-replacement-market
UK Healthcare Report: https://www.delveinsight.com/report-store/uk-healthcare-outlook-report
Attention Deficit Hyperactivity Disorder Market: https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Brucellosis Market: https://www.delveinsight.com/report-store/brucellosis-market
Coronary Angioplasty Market: https://www.delveinsight.com/report-store/coronary-stents-market-market
NK Cell Therapy Market: https://www.delveinsight.com/report-store/nk-cell-therapy-market
Scoliosis Market: https://www.delveinsight.com/report-store/scoliosis-market
Surgical Site Infections Market: https://www.delveinsight.com/report-store/surgical-site-infections-ssi-market
Attention Deficit Hyperactivity Disorder ADHD Market: https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Catheter Stabilization Devices Market: https://www.delveinsight.com/report-store/catheter-stabilization-securement-device-market
Diabetic Wound Market: https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market
Dyspepsia Market: https://www.delveinsight.com/report-store/functional-dyspepsia-market-share
Indwelling Catheters Market: https://www.delveinsight.com/report-store/indwelling-catheters-market
Orthopedic Splints Device Market: https://www.delveinsight.com/report-store/orthopedic-splints-market
Sepsis Market: https://www.delveinsight.com/report-store/sepsis-market
Overactive Bladder Syndrome Market: https://www.delveinsight.com/report-store/overactive-bladder-market
Spinal Trauma Devices Market: https://www.delveinsight.com/report-store/spinal-trauma-devices-market-market
Temporomandibular Disorders Market: https://www.delveinsight.com/report-store/temporomandibular-disorders-market
Viscosupplementation Devices Market: https://www.delveinsight.com/report-store/viscosupplementation-devices-market
Vitreoretinal Surgery Devices Market: https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
Advanced Liver Cancer Market: https://www.delveinsight.com/report-store/liver-cancer-market
Gene Therapy in CNS Disorder Market: https://www.delveinsight.com/report-store/gene-therapy-in-cns-disorder-market
Lice Infestations Market: https://www.delveinsight.com/report-store/lice-infestations-market
Plantar Fasciitis Market: https://www.delveinsight.com/report-store/plantar-fasciitis-market
Biopsy Devices Market: https://www.delveinsight.com/report-store/biopsy-devices-market
Endoscopic Ultrasound Market: https://www.delveinsight.com/report-store/endoscopic-ultrasound-market
Healthcare Consulting Solutions: https://www.delveinsight.com/consulting
Pelvic Organ Prolapse Market: https://www.delveinsight.com/report-store/pelvic-organ-prolapse-market
Pulmonary Emphysema Market: https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market
Schistosomiasis Market: https://www.delveinsight.com/report-store/schistosomiasis-market
Testicular Neoplasm Market: https://www.delveinsight.com/report-store/testicular-neoplasm-market
Tourette Syndrome Market: https://www.delveinsight.com/report-store/tourette-syndrome-market
Wound Healing Devices Market: https://www.delveinsight.com/report-store/wound-healing-devices-market
Chronic Neuropathic Pain Market: https://www.delveinsight.com/report-store/chronic-neuropathic-pain-market
Fabry Disease Market: https://www.delveinsight.com/report-store/fabry-disease-market
Transcatheter Treatment Market: https://www.delveinsight.com/report-store/transcatheter-treatment-market
SGLT2 Inhibitors Market: https://www.delveinsight.com/report-store/sglt2-inhibitors-market
Surgical Lasers Market: https://www.delveinsight.com/report-store/surgical-lasers-market
Stem Cell Market: https://www.delveinsight.com/report-store/stem-cell-market
Myeloproliferative Neoplasms Market: https://www.delveinsight.com/report-store/myeloproliferative-neoplasms-market
Pacemakers Market: https://www.delveinsight.com/report-store/pacemakers-market
Urea Cycle Disorders Market: https://www.delveinsight.com/blog/urea-cycle-disorder-market
Varicose Vein Treatment Devices Market: https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
Bone Growth Stimulator Market: https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Intraocular Lens Market: https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
Lymphoedema Market: https://www.delveinsight.com/report-store/lymphedema-market
Somatotropin Deficiency Market: https://www.delveinsight.com/report-store/somatotropin-deficiency-market
Skin Neoplasm Market: https://www.delveinsight.com/report-store/nonmelanoma-skin-cancer-market
Antibody Drug Conjugate Market: https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services
Surgical Mask & Respirator Market: https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Meibomian Gland Dysfunction Market: https://www.delveinsight.com/report-store/meibomian-gland-dysfunction-pipeline-insight
Novel Drug Delivery Devices Market: https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Total Knee Arthroplasty Market: https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Asperger Syndrome Market: https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market
Medical Marijuana Market: https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Lactose Intolerance Market: https://www.delveinsight.com/report-store/lactose-intolerance-market
Microscopy Device Market: https://www.delveinsight.com/sample-request/microscopy-device-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.